Table 1 Different demographic, clinical and laboratory data between the two studied groups
From: PCDH17 gene promoter methylation status in a cohort of Egyptian women with epithelial ovarian cancer
Parameter | Control group | Patient group | P value |
|---|---|---|---|
Age (years) | |||
 Mean ± SD | 49.08 ± 10.9 | 45.88 ± 13.4 | 0.359 |
Pregnancy | |||
 Median (IQR) | 3 (3-4) | 2 (0-3) | 0.015* |
Parity | |||
 Median (IQR) | 3 (3-4) | 2.12 (0-3) | 0.025* |
Lactation | 22/25 | 14/25 | 0.012* |
Menopause | 9/25 | 6/25 | 0.355 |
Tubal ligation | 0/25 | 1/25 | 0.49 |
Oral Contraceptive Pills | 1/25 | 2/25 | 1 |
Complaints/symptoms | |||
 Abdominal pain | 14/25 | 19/25 | 0.136 |
 Distension | 5/25 | 13/25 | 0.018* |
 Bleeding | 13/25 | 2/25 | 0.001* |
 Constipation | 1/25 | 1/25 | FEp = 1.0 |
 Weight loss | 0/25 | 2/25 | FEp = 0.49 |
 Discharge | 0/25 | 1/25 | FEp = 1 |
 Heaviness | 1/25 | 0/25 | FEp = 1 |
 Oligomenorrhea | 0/25 | 1/25 | FEp = 1 |
 Amenorrhea | 0/25 | 1/25 | FEp = 1 |
CA125 (U/ml) | |||
 Median (IQR) | 15.8 (13.7-31.3) | 175 (68.7-766) | < 0.001* |